# STERIS plc Moat

Status: published. Policy: company-analysis-1.

STERIS demonstrates realized pricing power, growing demand and established technical and service capabilities. The passages do not establish that these capabilities create durable switching costs, protected intellectual property, relative cost advantages or efficient scale. This is insufficient evidence of structural protection, rather than demonstrated competitive weakness. Recent AST volume declines and AST and Life Sciences margin compression temper otherwise favorable operating evidence.

## switching_costs

Installed equipment support, maintenance and AST process-validation services create ongoing customer relationships and potential operational switching friction. The disclosed activities are current; substantial switching costs remain unproven.

Durability: Equipment support and validation involvement could sustain relationships, but the passages disclose neither replacement costs nor customer renewal behavior. Maintenance and extended-warranty contracts are generally cancellable without penalty.

Risks: Purchase-order purchasing and penalty-free cancellation limit contractual protection. AST volume declined in the latest quarter despite higher prices; the cause is not established.

Invalidation: The switching-cost hypothesis would be undermined by demonstrated customer transfers without meaningful revalidation expense, disruption or equipment incompatibility, or persistent service customer losses despite competitive service quality.

Competitors: BBraun, Crothall, Olympus, Pentax
## intangible_assets

STERIS has technical personnel, proprietary technology protections and operations subject to regulatory approval. These establish capabilities and compliance requirements, but do not demonstrate exclusive technology or a durable advantage over qualified competitors.

Durability: Technical expertise may accumulate over time, but patent scope, remaining protection periods and comparative approval barriers are absent. The issuer explicitly describes its intellectual-property protection as limited.

Risks: Intense competition, technological substitution and loss of regulatory approvals could erode differentiation. Realized pricing supports current commercial strength but does not establish its structural source.

Invalidation: The differentiation hypothesis would be undermined by equivalent competing offerings consistently displacing STERIS on price, loss of essential approvals, or loss of proprietary protection followed by sustained customer losses or price concessions.

Competitors: 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron, Wassenburg
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026039136/ste-20260331.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026039136/ste-20260331.htm) · 2026-05-29
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026054830/ste-20260630.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026054830/ste-20260630.htm) · 2026-08-07
- [https://www.sec.gov/Archives/edgar/data/1757898/000119312526267599/d142920ddef14a.htm](https://www.sec.gov/Archives/edgar/data/1757898/000119312526267599/d142920ddef14a.htm) · 2026-06-11
- [https://www.sec.gov/Archives/edgar/data/1757898/000175789825000005/ste-20250331.htm](https://www.sec.gov/Archives/edgar/data/1757898/000175789825000005/ste-20250331.htm) · 2025-05-29
- [https://www.sec.gov/Archives/edgar/data/1757898/000175789824000008/ste-20240331.htm](https://www.sec.gov/Archives/edgar/data/1757898/000175789824000008/ste-20240331.htm) · 2024-05-29
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026006055/ste-20251231.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026006055/ste-20251231.htm) · 2026-02-06

[JSON](https://beanvest.com/stock/ste/moat.json)